PortalPublikationenDocetaxel, oxaliplatin and capecitabine (TEX regimen) in pat...

Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study

Standard

Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. / Stein, Alexander; Arnold, Dirk; Thuss-Patience, Peter C; Moehler, Markus; Grothe, Wilfried; Seufferlein, Thomas; Reinacher-Schick, Anke; Geissler, Michael; Hofheinz, Ralf-Dieter; Schmoll, Hans-Joachim.

in: ACTA ONCOL, Jahrgang 53, Nr. 3, 03.2014, S. 392-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stein, A, Arnold, D, Thuss-Patience, PC, Moehler, M, Grothe, W, Seufferlein, T, Reinacher-Schick, A, Geissler, M, Hofheinz, R-D & Schmoll, H-J 2014, 'Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study', ACTA ONCOL, Jg. 53, Nr. 3, S. 392-8. https://doi.org/10.3109/0284186X.2013.833346

APA

Stein, A., Arnold, D., Thuss-Patience, P. C., Moehler, M., Grothe, W., Seufferlein, T., Reinacher-Schick, A., Geissler, M., Hofheinz, R-D., & Schmoll, H-J. (2014). Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. ACTA ONCOL, 53(3), 392-8. https://doi.org/10.3109/0284186X.2013.833346

Vancouver

Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T et al. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. ACTA ONCOL. 2014 Mär;53(3):392-8. https://doi.org/10.3109/0284186X.2013.833346

Bibtex

@article{016546074c3b47508a9e9e95542b0b28,
title = "Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study",
abstract = "UNLABELLED: Three drug taxane-based regimens have shown activity in patients with metastatic or locally advanced gastric or gastro-esophageal cancer (GC/GEC). Limited tolerability of these regimens warrants treatment modification, particularly in regard of the proven equivalence of oxaliplatin and cisplatin as well as capecitabine and 5FU. Thus, a regimen with docetaxel (T), oxaliplatin (E) and capecitabine (X) was established and evaluated.METHODS: Patients with metastatic or locally advanced GC/GEC, adequate organ function, ECOG PS 0-2 were enrolled. TEX regimen was administered as defined by the phase I trial with T 35 mg/m(2) and E 70 mg/m(2) on days (d) 1, 8 and X 800 mg/m(2) bid on d 1-14 every 22 days. Primary endpoint was progression free survival (PFS) rate after 6 months.RESULTS: Altogether 70 patients (15 phase I; 55 phase II) were eligible for analysis. Results of the phase II part were as follows: most common grade toxicities diarrhea (30%), nausea/vomiting and infections, PFS rate after 6 months 56.3%, response rate 43%, median PFS 6.9 and overall survival 13 months, respectively.CONCLUSION: The TEX regimen show similar efficacy compared to other infusional 5FU-based taxane and platinum containing triplets, but the reduced tolerability, in particular grade 3 diarrhea, limits the feasibility.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Disease-Free Survival, Esophageal Neoplasms, Female, Fluorouracil, Humans, Male, Middle Aged, Organoplatinum Compounds, Stomach Neoplasms, Taxoids, Treatment Outcome",
author = "Alexander Stein and Dirk Arnold and Thuss-Patience, {Peter C} and Markus Moehler and Wilfried Grothe and Thomas Seufferlein and Anke Reinacher-Schick and Michael Geissler and Ralf-Dieter Hofheinz and Hans-Joachim Schmoll",
year = "2014",
month = mar,
doi = "10.3109/0284186X.2013.833346",
language = "English",
volume = "53",
pages = "392--8",
journal = "ACTA ONCOL",
issn = "0284-186X",
publisher = "informa healthcare",
number = "3",

}

RIS

TY - JOUR

T1 - Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study

AU - Stein, Alexander

AU - Arnold, Dirk

AU - Thuss-Patience, Peter C

AU - Moehler, Markus

AU - Grothe, Wilfried

AU - Seufferlein, Thomas

AU - Reinacher-Schick, Anke

AU - Geissler, Michael

AU - Hofheinz, Ralf-Dieter

AU - Schmoll, Hans-Joachim

PY - 2014/3

Y1 - 2014/3

N2 - UNLABELLED: Three drug taxane-based regimens have shown activity in patients with metastatic or locally advanced gastric or gastro-esophageal cancer (GC/GEC). Limited tolerability of these regimens warrants treatment modification, particularly in regard of the proven equivalence of oxaliplatin and cisplatin as well as capecitabine and 5FU. Thus, a regimen with docetaxel (T), oxaliplatin (E) and capecitabine (X) was established and evaluated.METHODS: Patients with metastatic or locally advanced GC/GEC, adequate organ function, ECOG PS 0-2 were enrolled. TEX regimen was administered as defined by the phase I trial with T 35 mg/m(2) and E 70 mg/m(2) on days (d) 1, 8 and X 800 mg/m(2) bid on d 1-14 every 22 days. Primary endpoint was progression free survival (PFS) rate after 6 months.RESULTS: Altogether 70 patients (15 phase I; 55 phase II) were eligible for analysis. Results of the phase II part were as follows: most common grade toxicities diarrhea (30%), nausea/vomiting and infections, PFS rate after 6 months 56.3%, response rate 43%, median PFS 6.9 and overall survival 13 months, respectively.CONCLUSION: The TEX regimen show similar efficacy compared to other infusional 5FU-based taxane and platinum containing triplets, but the reduced tolerability, in particular grade 3 diarrhea, limits the feasibility.

AB - UNLABELLED: Three drug taxane-based regimens have shown activity in patients with metastatic or locally advanced gastric or gastro-esophageal cancer (GC/GEC). Limited tolerability of these regimens warrants treatment modification, particularly in regard of the proven equivalence of oxaliplatin and cisplatin as well as capecitabine and 5FU. Thus, a regimen with docetaxel (T), oxaliplatin (E) and capecitabine (X) was established and evaluated.METHODS: Patients with metastatic or locally advanced GC/GEC, adequate organ function, ECOG PS 0-2 were enrolled. TEX regimen was administered as defined by the phase I trial with T 35 mg/m(2) and E 70 mg/m(2) on days (d) 1, 8 and X 800 mg/m(2) bid on d 1-14 every 22 days. Primary endpoint was progression free survival (PFS) rate after 6 months.RESULTS: Altogether 70 patients (15 phase I; 55 phase II) were eligible for analysis. Results of the phase II part were as follows: most common grade toxicities diarrhea (30%), nausea/vomiting and infections, PFS rate after 6 months 56.3%, response rate 43%, median PFS 6.9 and overall survival 13 months, respectively.CONCLUSION: The TEX regimen show similar efficacy compared to other infusional 5FU-based taxane and platinum containing triplets, but the reduced tolerability, in particular grade 3 diarrhea, limits the feasibility.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Deoxycytidine

KW - Disease-Free Survival

KW - Esophageal Neoplasms

KW - Female

KW - Fluorouracil

KW - Humans

KW - Male

KW - Middle Aged

KW - Organoplatinum Compounds

KW - Stomach Neoplasms

KW - Taxoids

KW - Treatment Outcome

U2 - 10.3109/0284186X.2013.833346

DO - 10.3109/0284186X.2013.833346

M3 - SCORING: Journal article

C2 - 24024696

VL - 53

SP - 392

EP - 398

JO - ACTA ONCOL

JF - ACTA ONCOL

SN - 0284-186X

IS - 3

ER -